Memorial Sloan Kettering Cancer Center: Hodgkin Disease trials

The registry lists 27 Hodgkin Disease studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 4 are open to participants now and 11 have results posted.

Phase 1 6Phase 2 15Phase 3 1No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Cord Blood Transplantation in Children and Young Adults With Blood CancerRecruitingNCT07566377Phase 2
• A Study of BV-AVD in People With Bulky Hodgkin LymphomaRecruitingNCT06377566Phase 2
• Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaRecruitingNCT03618550Phase 2
• Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and LymphomaRecruitingNCT01788839
• Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or LymphomaActive, not recruitingNCT04459416Phase 3Results posted
• Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood TransplantationCompletedNCT03434730Phase 2Results posted
• Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin LymphomaActive, not recruitingNCT03179917Phase 2Results posted
• Study of Atezolizumab in Relapsed or Refractory Hodgkin LymphomaTerminatedNCT03120676Phase 2Results posted
• Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02429375Phase 1/2Results posted
• Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01508312Phase 2Results posted
• Bendamustine HCL in Relapsed and Primary Refractory Hodgkin LymphomaCompletedNCT00705250Phase 2Results posted
• Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT00667615Phase 1/2Results posted
• Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCTCompletedNCT00648037Not applicableResults posted
• Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin LymphomaCompletedNCT00574496Phase 2Results posted
• Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00255723Phase 2Results posted
• A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell TransplantActive, not recruitingNCT05540340Phase 1
• A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)Active, not recruitingNCT03033914Phase 1/2
• Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin LymphomaCompletedNCT01868451Not applicable
• Communication Skills Intervention to Promote Transition Into SurvivorshipActive, not recruitingNCT01483664
• Prevalence+Significance of Paraneoplastic Autoantibodies in Many CancersCompletedNCT00608452
• Quality of Life Among Survivors of Hodgkin LymphomaCompletedNCT00598728
• A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)CompletedNCT00592111Phase 2
• Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)CompletedNCT00587873Phase 2
• Spectroscopy With Surface Coils and DecouplingCompletedNCT00581815Phase 1
• Behavioral Intervention For BMT/SCT SurvivorsCompletedNCT00579917
• Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell TransplantCompletedNCT00510315
• PS-341 in Treating Patients With Hematologic CancerCompletedNCT00006098Phase 1